TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9926153

Group type: EXPERIMENTAL
Intervention: Low dose allergen exposure (individualised to 25% of the total dose causing immediate and late response)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose allergen exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7923524

Group type: EXPERIMENTAL
Intervention: Curity tape without pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Leukopor tape without pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transpore tape without pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Curity tape with mastisol pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Leukopor tape with mastisol pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transpore tape with mastisol pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Curity tape with benzoin pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Leukopor tape with benzoin pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transpore tape with benzoin pretreatment
Number of subjects: 2
Study: 2452146

Group type: EXPERIMENTAL
Intervention: 45 Gy/18 fractions/4 1/2 weeks (arm 1)
Number of subjects: 273

Group type: COMPARATOR
Intervention: 31.2 Gy/4 fractions/4 weeks (arm 2)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 273
Study: 31729990

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 7637

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 7637

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 7637

Group type: EXPERIMENTAL
Intervention: Prior heart failure
Number of subjects: 7637
Study: 28027334

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 25391326

Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 23105144

Group type: EXPERIMENTAL
Intervention: 180 μg/week Pegylated interferon alfa-2a
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 90 μg/week Pegylated interferon alfa-2a
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined arms of Pegylated interferon alfa-2a
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sustained viral load <400 copies/mL
Number of subjects: 23
Study: 21320217

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to selected music from the evening before surgery to the second day after surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 60
Study: 18181909

Group type: EXPERIMENTAL
Intervention: RELIANCE G leads
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Comparative leads
Number of subjects: 1115
Study: 16644332

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg BID x 4 doses plus hydration
Number of subjects: 137

Group type: COMPARATOR
Intervention: Hydration alone (combined oral and rapid intravenous hydration)
Number of subjects: 137
Study: 12804346

Group type: EXPERIMENTAL
Intervention: Antiretroviral agent prescription
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CD4(+) cell counts
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: AIDS prevalence at baseline
Number of subjects: 214

Group type: COMPARATOR
Intervention: Healthcare service utilization
Number of subjects: 214

Group type: COMPARATOR
Intervention: Preventive and screening measures
Number of subjects: 214
Study: 10644538

Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg body mass)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucrose (1 g/kg body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 10
Study: 8888809

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 12.5 mg/m2/week x 3
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 10 mg/m2/week x 3
Number of subjects: 96

Group type: COMPARATOR
Intervention: Daunomycin (DNR) 45 mg/m2/week x 3
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 12.5 mg/m2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 10 mg/m2
Number of subjects: 96

Group type: COMPARATOR
Intervention: Daunomycin (DNR)
Number of subjects: 96
Study: 1672229

Group type: EXPERIMENTAL
Intervention: Topical treatment with tretinoin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Systemic treatment with etretinate
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 25
Study: 6210278

Group type: EXPERIMENTAL
Intervention: cis‐DDP (3 mg/kg iv day 1) and BLM (15‐20 mg iv continuously day 2‐6)
Number of subjects: 44

Group type: COMPARATOR
Intervention: MTX (30 mg/m2 iv day 1 + 6) and VDS (3 mg/m2 iv day 2 + 7)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: chemotherapeutically induced CR and PR
Number of subjects: 44

Group type: COMPARATOR
Intervention: non responders
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CR and PR achieved by surgery and/or x‐ray therapy
Number of subjects: 44
Study: 30443970

Group type: EXPERIMENTAL
Intervention: Complex learning task in simulated clinical immersion (SCI)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Simple learning task in simulated clinical immersion (SCI)
Number of subjects: 167
Study: 28207840

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation for 20 min twice a day and 19 g of lupin protein supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (only wearing the orthosis)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and lupin protein supplementation
Number of subjects: 13
Study: 25421703

Group type: EXPERIMENTAL
Intervention: Ligation anopexy (LA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional hemorrhoidectomy (CH)
Number of subjects: 200
Study: 24428805

Group type: EXPERIMENTAL
Intervention: High dose multiple micronutrient supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 22942294

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg plus clopidogrel 75 mg
Number of subjects: 300
Study: 20620518

Group type: EXPERIMENTAL
Intervention: Initial arterial revascularization (IAR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial portal revascularization (IPR) with rocuronium (1 mg/kg) infusion at 0.25 mg kg(‐1) h(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Initial portal revascularization (IPR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Initial arterial revascularization (IAR)
Number of subjects: 30
Study: 17463219

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) administered 0 hours relative to pramlintide (120 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) administered +1 hours relative to pramlintide (120 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) administered +2 hours relative to pramlintide (120 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) administered -2 hours relative to pramlintide (120 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) administered -1 hours relative to pramlintide (120 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0 hours relative to placebo)
Number of subjects: 24
Study: 15724362

Group type: EXPERIMENTAL
Intervention: Physical board and pieces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original chunking theory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cowan's proposal (2001)
Number of subjects: 0
Study: 11521914

Group type: EXPERIMENTAL
Intervention: Early fixation of major orthopaedic injuries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expedient and appropriate early treatment of fractures
Number of subjects: 0
Study: 9726384

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) with amoxycillin and clarithromycin for 1 week (RAC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole with amoxycillin and clarithromycin for 1 week (OAC)
Number of subjects: 100
Study: 7978412

Group type: EXPERIMENTAL
Intervention: HPCD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propylene glycol
Number of subjects: 24
Study: 2465076

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with low-dose leucovorin (20 mg/m2) intravenously for 5 days
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with high-dose leucovorin (200 mg/m2) intravenously for 5 days
Number of subjects: 208

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone (500 mg/m2 for 5 days)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with leucovorin (both doses)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with leucovorin
Number of subjects: 208
Study: 9954

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg and 100 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg and 500 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30387193

Group type: EXPERIMENTAL
Intervention: 12-hour overnight abstinence from snus (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Satiety condition (1 g of snus, 8 mg/g of nicotine administered 25 minutes before exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12-hour overnight abstinence from snus
Number of subjects: 16
Study: 28590567

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (<50 nmol/L) in late pregnancy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 198
Study: 26315736

Group type: EXPERIMENTAL
Intervention: DK crush stenting
Number of subjects: 419

Group type: COMPARATOR
Intervention: Culotte stenting
Number of subjects: 419
Study: 23055051

Group type: EXPERIMENTAL
Intervention: Exercise training (E)
Number of subjects: 17
Study: 21346492

Group type: EXPERIMENTAL
Intervention: PCL version with modified instructions
Number of subjects: 1691

Group type: COMPARATOR
Intervention: PCL version with standard instructions
Number of subjects: 1691

Group type: COMPARATOR
Intervention: PCL version with alternative modified instructions
Number of subjects: 1691
Study: 17851664

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 27
Study: 16861094

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg PO QD
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg PO QD
Number of subjects: 38
Study: 12515985

Group type: EXPERIMENTAL
Intervention: PRO‐SELF(c): Pain Control Program
Number of subjects: 0
Study: 10616841

Group type: EXPERIMENTAL
Intervention: Mutations in thiazide-sensitive Na-Cl cotransporter (TSC) gene
Number of subjects: 6
Study: 9156268

Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLI) with a large dose of donor lymphocytes (≥ 1 x 10(8)/kg) in group A (n = 8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLI) with escalating doses of cells (2 x 10(5) up to 2 x 10(8)/kg) in group B (n = 10)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLI with cells ≥ 1 x 10(8)/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLI with cells 2 x 10(7)/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLI with cells 2 x 10(6)/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLI with cells 2 x 10(5)/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with acute GVHD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients without acute GVHD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group A (DLI with ≥ 1 x 10(8)/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group B (DLI with escalating doses)
Number of subjects: 18
Study: 8465785

Group type: EXPERIMENTAL
Intervention: Inoue technique (n = 59)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Double-balloon technique (n = 61)
Number of subjects: 120
Study: 3463574

Group type: EXPERIMENTAL
Intervention: Flexible maintenance schedule based on spirochetes and/or motile rods
Number of subjects: 83

Group type: COMPARATOR
Intervention: Prophylaxes every 3 months
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 31736428

Group type: EXPERIMENTAL
Intervention: Active supplement containing Bacopa monniera, Panax quinquefolius ginseng, and whole coffee fruit extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31023347

Group type: EXPERIMENTAL
Intervention: Community-based care model with ongoing telephone-based support and home visits over 2 years
Number of subjects: 410

Group type: COMPARATOR
Intervention: Usual care (may involve a follow-up phone call or a home visit)
Number of subjects: 410
Study: 30241504

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (NaNO2) infusion at 240 μg/kg/hour for 2 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Allopurinol 150 mg twice daily (TD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril 5 mg TD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetazolamide 250 mg TD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26787601

Group type: EXPERIMENTAL
Intervention: 16‐week group‐based intervention adapted from the Diabetes Prevention Program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 25098612

Group type: COMPARATOR
Intervention: Standard needle (22G)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Core needle (22G)
Number of subjects: 80
Study: 22422897

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)-II
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HAM-D-17)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Inventory of Depressive Symptoms-Clinician (IDS-C)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Montgomery-Åsberg Depression Rating Scale (MADRS)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 30-item Geriatric Depression Scale (GDS-30)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Rating Scale-Revised (CESD-R)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS) Depression item
Number of subjects: 229
Study: 19027344

Group type: EXPERIMENTAL
Intervention: HVLAT (high-velocity low-amplitude thrust manipulation)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 17640489

Group type: EXPERIMENTAL
Intervention: 10 mg domperidone as free base with 20 mg omeprazole twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg domperidone as maleate salt with 20 mg omeprazole twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 mg domperidone as free base alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 mg domperidone as maleate salt alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg domperidone as free base with omeprazole
Number of subjects: 10
Study: 15915352

Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg, twice daily for 10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 10
Study: 11914204

Group type: EXPERIMENTAL
Intervention: 500 mg dose of levofloxacin by mouth preoperatively
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 15
Study: 9813433

Group type: EXPERIMENTAL
Intervention: Folic acid-fortified milk
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unfortified milk
Number of subjects: 49
Study: 7916852

Group type: EXPERIMENTAL
Intervention: Mobile telephone task during easy driving task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mobile telephone task during hard driving task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mobile telephone task during both easy and hard driving tasks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group during easy driving task
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group during hard driving task
Number of subjects: 40
Study: 2816479

Group type: COMPARATOR
Intervention: Estrogen monotherapy (n = 20)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Continuously combined estrogen/progestogen therapy (n = 20)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo for estrogen monotherapy (n = 25)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo for continuously combined estrogen/progestogen therapy (n = 23)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after hormone withdrawal)
Number of subjects: 88
Study: 56427

Group type: EXPERIMENTAL
Intervention: levodopa + benserazide (Madopar)
Number of subjects: 94

Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 94
Study: 31562408

Group type: EXPERIMENTAL
Intervention: Time pressure during clinical decision-making exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: No time pressure (control condition)
Number of subjects: 40
Study: 27618877

Group type: EXPERIMENTAL
Intervention: Cognitive-narrative program (4 sessions: recalling, cognitive and emotional subjectivization, metaphorization, projecting)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 29
Study: 26591395

Group type: EXPERIMENTAL
Intervention: Switch therapy (SWT) - switching from IV to oral antibiotics within 24 hours after clinical improvement
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group - treated as routine general practice
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Switch therapy (SWT)
Number of subjects: 57
Study: 24219860

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 molecule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22808810

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 3 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cut-off value of 8 mm for IPP
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cut-off value of 16 for IPSS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cut-off value of 40 gm for PS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cut-off value of 800 ml for RU
Number of subjects: 64
Study: 19275274

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16786236

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 80 mg/day)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Moderate statin therapy (pravastatin 40 mg/day)
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Patients with LDL < 70 mg/dL
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Patients with CRP < 2 mg/L
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Patients with LDL < 70 mg/dL and CRP < 2 mg/L
Number of subjects: 4162
Study: 15383180

Group type: EXPERIMENTAL
Intervention: Concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fixed combination of latanoprost 0.005%/timolol 0.5% once daily (LT group: 22 patients)
Number of subjects: 44
Study: 12539556

Group type: EXPERIMENTAL
Intervention: Xiaokuiling prescription (XKL)
Number of subjects: 0
Study: 9397242

Group type: EXPERIMENTAL
Intervention: OPC‐21268 (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OPC‐21268
Number of subjects: 40
Study: 7968562

Group type: EXPERIMENTAL
Intervention: Observation of drooling in clients identified as drooling
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sampling of drooling amounts in 2 clients identified as drooling
Number of subjects: 2
Study: 2822298

Group type: EXPERIMENTAL
Intervention: Methoxamine (alpha‐1 adrenoceptor agonist)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thymoxamine (alpha‐1 adrenoceptor antagonist)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 6
Study: 29557858

Group type: EXPERIMENTAL
Intervention: Improved caregiver depressive symptoms
Number of subjects: 156

Group type: COMPARATOR
Intervention: No significant changes in caregiver depressive symptoms
Number of subjects: 156

Group type: COMPARATOR
Intervention: Worsening caregiver depressive symptoms
Number of subjects: 156
Study: 27618516

Group type: EXPERIMENTAL
Intervention: Mung bean bag (MB) exercise group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Firm surface (FS) exercise group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 25184981

Group type: EXPERIMENTAL
Intervention: Obstetrics mannequin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Birthing pelvis model
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both simulators (combined results)
Number of subjects: 110
Study: 23603346

Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 19732095

Group type: EXPERIMENTAL
Intervention: Spironolactone (300 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (300 mg)
Number of subjects: 15
Study: 18200024

Group type: EXPERIMENTAL
Intervention: Inhaled racemic epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15994288

Group type: EXPERIMENTAL
Intervention: PSC-833
Number of subjects: 419

Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine
Number of subjects: 419